https://www.avient.com/sites/default/files/2023-11/AVNT Q3 2023 Earnings Presentation - Website.pdf
Avient’s chief operating decision maker uses these financial measures to monitor and evaluate the ongoing performance of Avient and each business segment and to allocate resources.
Each of such adjustments has not yet occurred, are out of Avient’s control and/or cannot be reasonably predicted.
For the same reasons, Avient is unable to address the probable significance of the unavailable information.
https://www.avient.com/sites/default/files/2022-05/AVNT May IR Presentation w Non GAAP Recs.pdf
Avient’s chief operating decision maker uses these financial measures to monitor and evaluate the ongoing performance of Avient and each business segment and to allocate resources.
PEERS Avient today reflects 2022 estimated EBITDA of $635M and revenue of $5,100.
Avient pro forma reflects 2022 estimated EBITDA of $660M and revenue of $3,740M.
https://www.avient.com/sites/default/files/2022-03/Sustainability ESG Disclosures_Animal Testing Policy.pdf
Animal Testing Policy AVIENT CORPORATION AND SUBSIDIARIES In the normal course of doing business, Avient is required to conduct testing to ensure the safety of its products.
Avient is committed to replacing, reducing and refining the use of animal testing by applying the following practices: • Replace – Before any vertebrae testing, Avient will investigate the use of alternative methods and approaches, including use of data that is already publically available, computational toxicology models and read-across to available data for similar substances. • Reduce – Avient will only consider animal testing if it is a legal requirement, or to ensure the safety of our products, when no suitable alternatives are available.
In these cases, Avient commits to minimize the number of animals as much as possible. • Refine – Avient does not have animal testing facilities, any necessary studies are conducted by external testing facilities that are certified by Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) and that are committed to utilise methods that minimize pain, discomfort and distress before, during and after the test period.
https://www.avient.com/sites/default/files/2020-07/woonkeatmoh_0.pdf
Moh also served as Vice President of Asia, where he strengthened a One Avient approach internally and externally with customers, regional leaders and associations, as Avient has invested for growth in Asia.
He is based in Avient’s world headquarters located outside Cleveland, Ohio.
Avient Corporation • 33587 Walker Road • Avon Lake, Ohio 44012 • 440.930.1000 • www.avient.com
https://www.avient.com/sites/default/files/2020-07/holgerkronimus_0.pdf
Kronimus joined Avient in March 1999, and in addition to leading the company’s engineered materials business in Europe and India, also serves as Avient’s legal representative in the region, responsible for building and maintaining relationships with local governments and associations.
In previous roles at Avient, Mr.
Avient Corporation • 33587 Walker Road • Avon Lake, Ohio 44012 • 440.930.1000 • www.avient.com
https://www.avient.com/sites/default/files/2020-10/edgetek-peek-product-selection-guide.pdf
Avient’s specialty Edgetek™ PEEK formulations are capable of withstanding extreme operating environments, and should be considered for use particularly where other engineered polymers have failed.
Avient makes no warranties or guarantees respecting suitability of either Avient’s products or the information for your process or end-use application.
Avient makes no warranties or guarantees respecting suitability of either Avient’s products or the information for your process or end-use application.
https://www.avient.com/sites/default/files/2023-01/Mevopur Healthcare Colorants and Formulations Special Effects Application Bulletin_0.pdf
Copyright © 2022, Avient Corporation.
Avient makes no warranties or guarantees respecting suitability of either Avient’s products or the information for your process or end-use application.
Avient is committed to the needs of our healthcare customers.
https://www.avient.com/sites/default/files/2022-12/Mevopur Colors for Ophthalmic Closures Application Bulletin_A4.pdf
Copyright © 2022, Avient Corporation.
Avient makes no warranties or guarantees respecting suitability of either Avient’s products or the information for your process or end-use application.
Avient is committed to the needs of our healthcare customers.
https://www.avient.com/sites/default/files/2024-07/Composite Heat Release Technology Product Bulletin.pdf
Avient’s Composite Heat Release technology leverages the concept of thermal inertia to reduce internal barrel temperatures.
For more information, please contact Avient to speak with our Outdoor High Performance material experts. 1.844.4AVIENT www.avient.com Copyright © 2024, Avient Corporation.
Avient makes no warranties or guarantees respecting suitability of either Avient’s products or the information for your process or end-use application.
https://www.avient.com/sites/default/files/2023-06/EZR Gun Grip Case Study.pdf
THE SOLUTION Avient worked with EZR Sport to develop a solution and CORE™ Non-Phthalate Plastisols were chosen as a potential fit.
CORE Non-Phthalate Plastisols are also included in Avient’s No Surprises Pledge, made to all customers and markets across the globe.
Once emptied, EZR can collapse and stack the totes to be collected by Avient for future deliveries.